HC Wainwright & Co. Reiterates Buy on Evommune, Maintains $50 Price Target

Evommune, Inc.

Evommune, Inc.

EVMN

0.00

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE: EVMN) with a Buy and maintains $50 price target.